Analysts Issue Forecasts for CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Caribou Biosciences in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will earn ($2.17) per share for the year. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). The business had revenue of $2.35 million for the quarter, compared to analyst estimates of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Several other analysts also recently commented on CRBU. Wall Street Zen downgraded Caribou Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

Caribou Biosciences Stock Down 4.3%

NASDAQ:CRBU traded down $0.05 on Wednesday, hitting $1.11. The stock had a trading volume of 1,162,421 shares, compared to its average volume of 1,358,770. The business's fifty day moving average is $0.93 and its 200 day moving average is $1.26. The company has a market cap of $103.24 million, a PE ratio of -0.67 and a beta of 2.44. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.00.

Institutional Trading of Caribou Biosciences

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after purchasing an additional 2,062,563 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in Caribou Biosciences by 28.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after acquiring an additional 467,738 shares in the last quarter. Two Sigma Advisers LP lifted its position in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after acquiring an additional 416,600 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Caribou Biosciences by 19.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock valued at $1,317,000 after acquiring an additional 234,052 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in Caribou Biosciences by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company's stock valued at $1,779,000 after acquiring an additional 214,239 shares in the last quarter. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.